49.72
49.72 (0%)
As of Feb 14, 2025
CRISPR Therapeutics AG [CRSP]
Source:
Company Overview
Crispr Therapeutics Ag is a leading gene editing company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA.
| Country | United States |
| Headquarters | zug |
| Phone Number | 6173154600 |
| Industry | manufacturing |
| CEO | Samarth Kulkarni |
| Website | crisprtx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $37.3 |
| Operating Profit | $-466.6 |
| Net Income | $-366.3 |
| Net Cash | $-91.3 |
Profit Ratios
| Gross Margin | $37.3 |
| Operating Margin | -1,250.4 |
| Profit as % of Revenues | -10.2% |
| Profit as % of Assets | -16.4% |
| Profit as % of Stockholder Equity | -19% |
Management Effectiveness
| Return on Equity | -19% |
| Return on Assets | -16.3% |
| Turnover Ratio | 1.7% |
| EBITA | $-466.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $2,242 |
| Total Liabilities | $310 |
| Operating Cash Flow | $-142.8 |
| Investing Cash Flow | $-280.5 |
| Financing Cash Flow | $332 |
